This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Real, P. J. Articles by Fernandez-Luna, J. L. Search for Related Content PubMed PubMed Citation Articles by Real, P. J. Articles by Fernandez-Luna, J. L.

Breast Cancer Cells Can Evade Apoptosis-Mediated Selective Killing by a Novel Small Molecule Inhibitor of Bcl-2

¹ Unidad de Genetica Molecular and ² Servicio de Oncologia Medica, Hospital Universitario Marques de Valdecilla, Servicio Cantabro de Salud, Santander, Spain; and ³ Departments of Internal Medicine and Medicinal Chemistry, and Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan

Proteins of the Bcl-2 family are key regulators of caspase activation and apoptosis. Some members of this family, notably Bcl-2 and Bcl-x_L, are overexpressed in cancer cells, which have been associated with chemoresistance. We have designed and synthesized a small molecule inhibitor of Bcl-2, named YC137, and studied its role in cancer cells. In vitro studies showed that YC137 inhibits the binding of the Bid BH3 peptide to Bcl-2, thus disrupting an interaction essential for the antiapoptotic activity of Bcl-2. This inhibitor induces apoptosis of hematopoietic progenitors overexpressing Bcl-2 but not Bcl-x_L and breast cancer cells that express high levels of Bcl-2. On the contrary, a variety of normal primary cells, including CD34⁺ progenitors, myoblasts, and peripheral blood mononuclear cells, do not respond to the inhibitor. A breast cancer cell line resistant to YC137 was generated. Analysis of resistant cells revealed a reduced expression of Bcl-2, which correlated with low activation of signal transducer and activator of transcription-3 (Stat3) and reduced expression of the human epidermal growth factor receptor-2 (HER2). Of note, YC137-resistant cells were more sensitive to apoptosis induced by chemotherapy. Because HER2 has not been linked previously to the Stat3-Bcl-2 transcriptional pathway, we additionally confirmed that specific blockade of HER2 in breast cancer cells resulted in down-regulation of Stat3 activity and reduced levels of Bcl-2. Consistently, HER2 blockade led to YC137 resistance. These data provide evidence for the selective killing of tumor cells by YC137 and represent the first example of in vitro selection of cancer cells refractory to a Bcl-2 inhibitor.

This article has been cited by other articles:

				K. F. Wan, S.-L. Chan, S. K. Sukumaran, M.-C. Lee, and V. C. Yu Chelerythrine Induces Apoptosis through a Bax/Bak-independent Mitochondrial Mechanism J. Biol. Chem., March 28, 2008; 283(13): 8423 - 8433. [Abstract] [Full Text] [PDF]

				B. P. Gomez, R. B. Riggins, A. N. Shajahan, U. Klimach, A. Wang, A. C. Crawford, Y. Zhu, A. Zwart, M. Wang, and R. Clarke Human X-Box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines FASEB J, December 1, 2007; 21(14): 4013 - 4027. [Abstract] [Full Text] [PDF]

				B. D. Zeitlin, E. Joo, Z. Dong, K. Warner, G. Wang, Z. Nikolovska-Coleska, S. Wang, and J. E. Nor Antiangiogenic Effect of TW37, a Small-Molecule Inhibitor of Bcl-2. Cancer Res., September 1, 2006; 66(17): 8698 - 8706. [Abstract] [Full Text] [PDF]

				A. Yoshida, H. Takemura, H. Inoue, T. Miyashita, and T. Ueda Inhibition of Glutathione Synthesis Overcomes Bcl-2-Mediated Topoisomerase Inhibitor Resistance and Induces Nonapoptotic Cell Death via Mitochondrial-Independent Pathway Cancer Res., June 1, 2006; 66(11): 5772 - 5780. [Abstract] [Full Text] [PDF]

				F. Manero, F. Gautier, T. Gallenne, N. Cauquil, D. Gree, P.-F. Cartron, O. Geneste, R. Gree, F. M. Vallette, and P. Juin The Small Organic Compound HA14-1 Prevents Bcl-2 Interaction with Bax to Sensitize Malignant Glioma Cells to Induction of Cell Death. Cancer Res., March 1, 2006; 66(5): 2757 - 2764. [Abstract] [Full Text] [PDF]

				E. S. Henson, X. Hu, and S. B. Gibson Herceptin Sensitizes ErbB2-Overexpressing Cells to Apoptosis by Reducing Antiapoptotic Mcl-1 Expression Clin. Cancer Res., February 1, 2006; 12(3): 845 - 853. [Abstract] [Full Text] [PDF]